Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""transplantation conditioning"" wg kryterium: Temat


Tytuł :
Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen.
Autorzy :
Jiang H; Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
Geng L; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Wan X; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Song K; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Tong J; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Zhu X; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.; Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Tang B; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Yao W; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Zhang X; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Sun G; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Zhang L; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.
Sun Z; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China.; Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Liu H; Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, China. .; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Road, Hefei, Anhui, China. .; Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Sep; Vol. 114 (3), pp. 381-389. Date of Electronic Publication: 2021 Jun 12.
Typ publikacji :
Journal Article
MeSH Terms :
Cord Blood Stem Cell Transplantation/*adverse effects
Cystitis/*epidemiology
Cystitis/*etiology
Hemorrhage/*epidemiology
Hemorrhage/*etiology
Transplantation Conditioning/*adverse effects
Adolescent ; Adult ; Aged ; Child ; Cord Blood Stem Cell Transplantation/methods ; Cystitis/diagnosis ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hemorrhage/diagnosis ; Humans ; Incidence ; Male ; Middle Aged ; Pre-Exposure Prophylaxis ; Prognosis ; Risk Factors ; Transplantation Conditioning/methods ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Autorzy :
Edahiro T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Kawase T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Nagoshi H; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Fujino K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Toishigawa K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Miyama T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Mino T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Yoshida T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Morioka T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Hirata Y; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Noma M; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Fujii T; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Nishizawa M; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Fukushima N; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 186-198.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hematologic Neoplasms/*therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Busulfan/administration & dosage ; Combined Modality Therapy ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/mortality ; Humans ; Male ; Melphalan/administration & dosage ; Middle Aged ; Myeloablative Agonists/administration & dosage ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Young Adult
Czasopismo naukowe
Tytuł :
A high transfusion burden following an ambulatory-allogeneic hematopoietic cell transplantation using reduced-intensity conditioning is associated with adverse outcomes.
Autorzy :
Jaime-Pérez JC; Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico. Electronic address: .
Hernández-Coronado M; Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Salazar-Cavazos L; Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Marfil-Rivera LJ; Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Gómez-Almaguer D; Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Pokaż więcej
Źródło :
Blood cells, molecules & diseases [Blood Cells Mol Dis] 2021 May; Vol. 88, pp. 102537. Date of Electronic Publication: 2021 Jan 12.
Typ publikacji :
Journal Article
MeSH Terms :
Erythrocyte Transfusion*
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Platelet Transfusion*
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Adolescent ; Adult ; Aged ; Female ; Graft vs Host Disease/etiology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Analysis ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Young Adult
Czasopismo naukowe
Tytuł :
Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts.
Autorzy :
Lu Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Xiong M; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Sun RJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Zhao YL; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Zhang JP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Cao XY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Liu DY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Wei ZJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Zhou JR; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 134-143.
Typ publikacji :
Journal Article
MeSH Terms :
Congenital Bone Marrow Failure Syndromes/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Graft Survival ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Survival Analysis ; Transplantation Conditioning/adverse effects ; Unrelated Donors ; Young Adult
Czasopismo naukowe
Tytuł :
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.
Autorzy :
Novelli S; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital Sant Pau, Barcelona, Spain. Electronic address: .
Bento L; Hematology Department, Son Espases University Hospital, Palma de Mallorca, Spain.
Garcia I; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital Sant Pau, Barcelona, Spain.
Prieto L; Hematology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
López L; Hematology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
Gutierrez G; Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Hernani R; Hematology Department, Hospital Clínico de Valencia, Valencia, Spain.
Pérez A; Hematology Department, Hospital Clínico de Valencia, Valencia, Spain.
Esquirol A; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital Sant Pau, Barcelona, Spain.
Solano C; Hematology Department, Hospital Clínico de Valencia, Valencia, Spain.
Bastos M; Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Dorado N; Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Rodríguez N; Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Sevilla, Spain.
Rodríguez G; Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Sevilla, Spain.
Piñana JL; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Montoro J; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Herrera P; Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Luna A; Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Parody R; Hematology Department, Institut Catala d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
Martín C; Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
García E; Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
López O; Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
Heras I; Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
Zanabili J; Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Moraleda JM; Hematology Department, Hospital Virgen de la Arrixaca, Murcia, Spain.
Yañez L; Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Gutierrez A; Hematology Department, Son Espases University Hospital, Palma de Mallorca, Spain.
Zudaire T; Hematology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Córdoba R; Hematology Department, Fundación Jiménez Díaz, Madrid, Spain.
Varela R; Hematology Department, Hospital Universitario de A Coruña, A Coruña, Spain.
Ferra C; Hematology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Martínez J; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Martínez C; Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Gonzalez-Barca E; Hematology Department, Institut Catala d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
Martino R; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital Sant Pau, Barcelona, Spain.
Caballero D; Hematology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
Pokaż więcej
Corporate Authors :
GELTAMO and GETH
Źródło :
Transplantation and cellular therapy [Transplant Cell Ther] 2021 Jun; Vol. 27 (6), pp. 493.e1-493.e8. Date of Electronic Publication: 2021 Mar 15.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Humans ; Killer Cells, Natural ; Neoplasm Recurrence, Local ; Registries ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.
Autorzy :
Jamy O; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. .
Chen A; Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Battles K; Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Francisco L; Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Salzman D; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bal S; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Di Stasi A; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Costa L; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bhatia R; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bhatia S; Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Jun; Vol. 56 (6), pp. 1364-1372. Date of Electronic Publication: 2021 Jan 08.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Bone Marrow ; Health Services Accessibility ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
Autorzy :
Mori T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. .
Kikuchi T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Yamazaki R; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Koda Y; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Saburi M; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Sakurai M; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Shigematsu N; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kato J; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Jun; Vol. 113 (6), pp. 877-883. Date of Electronic Publication: 2021 Mar 01.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Whole-Body Irradiation*
Benzylamines/*administration & dosage
Cyclams/*administration & dosage
Leukemia/*therapy
Adult ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
Autorzy :
Nakano N; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan. .
Takatsuka Y; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Kubota A; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Tokunaga M; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Miyazono T; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Tabuchi T; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Odawara J; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Tokunaga M; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Makino T; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Takeuchi S; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Ito Y; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Utsunomiya A; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Jun; Vol. 113 (6), pp. 861-871. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Cord Blood Stem Cell Transplantation*
Transplantation Conditioning*
Leukemia-Lymphoma, Adult T-Cell/*mortality
Leukemia-Lymphoma, Adult T-Cell/*therapy
Melphalan/*administration & dosage
Vidarabine/*analogs & derivatives
Adult ; Aged ; Allografts ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Survival Rate ; Vidarabine/administration & dosage
Czasopismo naukowe
Tytuł :
Physical Activity and Sleep Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A Pilot Study.
Autorzy :
Jurdi NE; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Nock N; Case Western Reserve University, Cleveland, Ohio.
Fu P; Case Western Reserve University, Cleveland, Ohio.
Cao S; Case Western Reserve University, Cleveland, Ohio.
Cotton JM; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Ali N; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Ravi G; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Pinto R; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Galloway E; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Kolke S; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Cooper B; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Tomlinson B; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Malek E; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Lance C; Cleveland Clinic, Cleveland, Ohio.
Kolk MJ; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Ferrari N; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Lee R; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
de Lima M; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Caimi PF; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio.
Metheny L; University Hospitals Seidman Cancer Center, Cleveland, Ohio; Case Western Reserve University, Cleveland, Ohio. Electronic address: .
Pokaż więcej
Źródło :
Transplantation and cellular therapy [Transplant Cell Ther] 2021 Jun; Vol. 27 (6), pp. 502.e1-502.e6. Date of Electronic Publication: 2021 Feb 19.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Exercise ; Humans ; Pilot Projects ; Prospective Studies ; Sleep ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders.
Autorzy :
Lima ACM; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Bonfim C; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Getz J; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Dornelles LN; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
do Amaral GB; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Petterle RR; Department of Integrative Medicine, Federal University of Paraná, Curitiba, Brazil.
Loth G; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Nabhan SK; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Pereira NF; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Pasquini R; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Pokaż więcej
Źródło :
HLA [HLA] 2021 Jun; Vol. 97 (6), pp. 493-504. Date of Electronic Publication: 2021 May 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Alleles ; Cyclophosphamide ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience.
Autorzy :
Bernard F; Paediatric Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland.
Uppungunduri CRS; CANSEARCH research laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Meyer S; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.; Teenage and Young Adult Cancer, The Christie NHS Foundation Trust, Manchester, UK.; Department of Haematology and Oncology, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Cummins M; Department of Paediatric Haematology and Bone Marrow Transplantation, Bristol Royal Hospital for Children, Bristol, UK.
Patrick K; Department of Paediatric Haematology, Sheffield Children's Hospital, Sheffield, UK.
James B; Department of Paediatric Oncology and Haematology, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Skinner R; Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK.
Tewari S; Department of Paediatric Haematology/Oncology, The Royal Marsden Hospital NHS Trust, Sutton, UK.
Carpenter B; Department of Haematology, University College London Hospitals NHS Trust, London, UK.
Wynn R; Department of Blood and Marrow Transplant, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Veys P; Department of Bone Marrow Transplant and Haematology, Great Ormond Street Hospital for Children, London, UK.
Amrolia P; Department of Bone Marrow Transplant and Haematology, Great Ormond Street Hospital for Children, London, UK.; Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Pokaż więcej
Corporate Authors :
UK Paediatric BMT group
Źródło :
British journal of haematology [Br J Haematol] 2021 May; Vol. 193 (4), pp. 804-813. Date of Electronic Publication: 2021 Apr 14.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Bone Marrow Transplantation*
Fanconi Anemia*/mortality
Fanconi Anemia*/therapy
Graft vs Host Disease*/mortality
Graft vs Host Disease*/prevention & control
Transplantation Conditioning*
Unrelated Donors*
Alemtuzumab/*administration & dosage
Cyclophosphamide/*administration & dosage
Adolescent ; Adult ; Allografts ; Child ; Child, Preschool ; Chronic Disease ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
Autorzy :
Iftikhar R; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan. Electronic address: .
Chaudhry QUN; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Anwer F; Department of Hematology, Medical Oncology, Tausig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, United States.
Neupane K; Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara 33700, Nepal.
Rafae A; Department of Internal Medicine, McLaren Flint Michigan State University, United States.
Mahmood SK; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Ghafoor T; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Shahbaz N; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Khan MA; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Khattak TA; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Shamshad GU; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Rehman J; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Farhan M; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Khan M; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Ansar I; Shifa College of Medicine, Islamabad 44000, Pakistan.
Ashraf R; King Edward Medical University, Lahore 54000, Pakistan.
Marsh J; Department of Hematological Medicine, King's College Hospital, Denmark Hill, London SE59RS, UK.
Satti TM; Shifa International Hospital, Islamabad 44000, Pakistan.
Ahmed P; Department of Hematology Oncology and Stem Cell Transplant, Quaid-e-Azam International Hospital, Islamabad 44000, Pakistan.
Pokaż więcej
Źródło :
Blood reviews [Blood Rev] 2021 May; Vol. 47, pp. 100772. Date of Electronic Publication: 2020 Oct 31.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Immunosuppression*
Transplantation Conditioning*
Anemia, Aplastic/*therapy
Graft Rejection/*prevention & control
Graft vs Host Disease/*prevention & control
Age Factors ; Allografts ; Antilymphocyte Serum/therapeutic use ; Cyclosporine/therapeutic use ; Humans ; Methotrexate/therapeutic use ; Risk Factors ; Unrelated Donors ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
Planned hematopoietic stem cell transplantation in a 17-month-old patient with high-risk acute myeloid leukemia and persistent SARS-CoV-2 infection.
Autorzy :
Cuzzubbo D; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.
Pegoraro F; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.; Department of Health Science, University of Florence, Florence, Italy.
Frenos S; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.
Casini T; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.
Galli L; Department of Health Science, University of Florence, Florence, Italy.; Pediatric Infectious Diseases Division, Meyer Children's University Hospital, Florence, Italy.
Gambineri E; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.; Department of Health Science, University of Florence, Florence, Italy.
Bambi F; Blood Bank, Meyer Children's University Hospital, Florence, Italy.
Tintori V; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.
Favre C; Pediatric Haematology/Oncology and HSCT Department, Meyer Children's University Hospital, Florence, Italy.
Pokaż więcej
Źródło :
Transfusion [Transfusion] 2021 May; Vol. 61 (5), pp. 1657-1659. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
COVID-19*/blood
COVID-19*/therapy
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/blood
Leukemia, Myeloid, Acute*/therapy
Transplantation Conditioning*
SARS-CoV-2/*metabolism
Humans ; Infant ; Male ; Transplantation, Homologous
Raport
Tytuł :
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Autorzy :
Craddock C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Jackson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Loke J; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Siddique S; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Hodgkinson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Mason J; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Andrew G; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Nagra S; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Malladi R; Addenbrookes Hospital, Cambridge, United Kingdom.
Peniket A; Churchill Hospital, Oxford, United Kingdom.
Gilleece M; St James's Hospital, Leeds, United Kingdom.
Salim R; Royal Liverpool University Hospital, United Kingdom.
Tholouli E; Manchester Royal Infirmary, Manchester, United Kingdom.
Potter V; Kings College Hospital, London, United Kingdom.
Crawley C; Addenbrookes Hospital, Cambridge, United Kingdom.
Wheatley K; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Protheroe R; Bristol Haematology and Oncology Centre, United Kingdom.
Vyas P; Churchill Hospital, Oxford, United Kingdom.
Hunter A; Leicester Royal Infirmary, United Kingdom.
Parker A; Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Wilson K; University Hospital Wales, United Kingdom.
Pavlu J; Imperial College Hospital, London, Unite Kingdom.
Byrne J; Centre for Clinical Haematology, Nottingham, United Kingdom.
Dillon R; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
Khan N; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
McCarthy N; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Mar 01; Vol. 39 (7), pp. 768-778. Date of Electronic Publication: 2020 Dec 29.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Stem Cell Transplantation*/adverse effects
Stem Cell Transplantation*/mortality
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/mortality
Amsacrine/*administration & dosage
Busulfan/*administration & dosage
Cytarabine/*administration & dosage
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myeloablative Agonists/*administration & dosage
Myelodysplastic Syndromes/*therapy
Vidarabine/*analogs & derivatives
Adult ; Aged ; Amsacrine/adverse effects ; Busulfan/adverse effects ; Cytarabine/adverse effects ; Female ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Humans ; Immunosuppressive Agents/adverse effects ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Myeloablative Agonists/adverse effects ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/pathology ; Progression-Free Survival ; Recurrence ; Time Factors ; Transplantation, Homologous ; United Kingdom ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation.
Autorzy :
Gjaerde LK; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ostrowski SR; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Minculescu L; Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Andersen NS; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Friis LS; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Kornblit B; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Petersen SL; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Schjødt I; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Sengeløv H; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło :
European journal of haematology [Eur J Haematol] 2021 Mar; Vol. 106 (3), pp. 417-424. Date of Electronic Publication: 2020 Dec 19.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Graft vs Host Disease/*blood
Graft vs Host Disease/*etiology
Vitamin E/*blood
Acute Disease ; Biomarkers ; Disease Susceptibility ; Female ; Graft vs Host Disease/diagnosis ; Humans ; Male ; Myeloablative Agonists/administration & dosage ; Postoperative Period ; Severity of Illness Index ; Time Factors ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation.
Autorzy :
Cheon J; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Lee YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Kweon K; Department of Psychiatry, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Koh S; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Min YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Park SH; Department of Laboratory Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Lee SH; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Kim HJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.
Choi Y; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea. .
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Feb; Vol. 29 (2), pp. 975-986. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation/*adverse effects
Quality of Life/*psychology
Survivors/*statistics & numerical data
Transplantation Conditioning/*adverse effects
Transplantation, Homologous/*adverse effects
Female ; Hematopoietic Stem Cell Transplantation/methods ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Male ; Middle Aged ; Republic of Korea ; Retrospective Studies ; Risk Factors ; Survival Rate ; Transplantation Conditioning/methods ; Transplantation Conditioning/mortality ; Transplantation, Homologous/methods ; Transplantation, Homologous/mortality
Czasopismo naukowe
Tytuł :
[Potential of ultrasound in allogeneic stem cell transplantation and transplant-related complications].
Autorzy :
Trenker C; Klinik für Hämatologie, Onkologie und Immunologie, UKGM Marburg und Philipps-Universität Marburg.
Dietrich CF; Klinik Beauside, Departement für Allgemeine Innere Medizin, Hirslanden Bern.
Klein S; Universitätsklinikum Mannheim, III. Medizinische Klinik.
Safai Zadeh E; Interdisziplinäres Ultraschallzentrum, UKGM Marburg.
Sohlbach K; Klinik für Hämatologie, Onkologie und Immunologie, UKGM Marburg und Philipps-Universität Marburg.
Neubauer A; Klinik für Hämatologie, Onkologie und Immunologie, UKGM Marburg und Philipps-Universität Marburg.
Burchert A; Klinik für Hämatologie, Onkologie und Immunologie, UKGM Marburg und Philipps-Universität Marburg.
Görg C; Interdisziplinäres Ultraschallzentrum, UKGM Marburg.
Pokaż więcej
Transliterated Title :
Potenzial des Ultraschalls bei allogener Stammzelltransplantation und transplantationsassoziierten Komplikationen.
Źródło :
Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2021 Apr; Vol. 59 (4), pp. 336-344. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Transplantation Conditioning*
Ultrasonography/*methods
Humans ; Transplantation, Homologous/adverse effects
Czasopismo naukowe
Tytuł :
Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.
Autorzy :
Jurgensen-Rauch A; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Gibbs S; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Farrell M; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Aries J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Grantham M; Department of Cytogenetics and Molecular Haematology, Barts Health NHS Trust, London, UK.
Eccersley L; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Gribben J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.; Barts Cancer Institute, Queen Mary University of London, London, UK.
Hallam S; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Oakervee H; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Cavenagh J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Davies J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.; Barts Cancer Institute, Queen Mary University of London, London, UK.
Sive J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Apr; Vol. 193 (2), pp. 420-423. Date of Electronic Publication: 2021 Mar 13.
Typ publikacji :
Letter
MeSH Terms :
Graft vs Host Disease/*prevention & control
Hematopoietic Stem Cell Transplantation/*adverse effects
Multiple Myeloma/*therapy
Transplantation Conditioning/*methods
Transplantation, Autologous/*methods
Adult ; Cytogenetics/methods ; Female ; Graft vs Host Disease/epidemiology ; Graft vs Host Disease/mortality ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Outcome Assessment, Health Care ; Progression-Free Survival ; Retrospective Studies ; Risk Assessment ; Transplantation Conditioning/statistics & numerical data
Opinia redakcyjna
Tytuł :
Determinants of cardiorespiratory fitness in very long-term survivors of allogeneic hematopoietic stem cell transplantation: a national cohort study.
Autorzy :
Myrdal OH; Department of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Box 4950 Nydalen, 0424, Oslo, Norway. .; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. .
Diep PP; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pediatric Oncology and Haematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Department of Pediatric Research, Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Ruud E; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pediatric Oncology and Haematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Brinch L; Department of Haematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Massey RJ; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Edvardsen E; Department of Physical Performance, The Norwegian School of Sport Sciences, Oslo, Norway.; Department of Pulmonary Medicine, Oslo University Hospital Ullevål, Oslo, Norway.
Kongerud J; Department of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Box 4950 Nydalen, 0424, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lund MB; Department of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Box 4950 Nydalen, 0424, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Sikkeland LI; Department of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Box 4950 Nydalen, 0424, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Apr; Vol. 29 (4), pp. 1959-1967. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Journal Article
MeSH Terms :
Cardiorespiratory Fitness/*physiology
Hematopoietic Stem Cell Transplantation/*methods
Survivors/*statistics & numerical data
Transplantation Conditioning/*methods
Adolescent ; Adult ; Cohort Studies ; Cross-Sectional Studies ; Female ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Male ; Middle Aged ; Survival Analysis ; Transplantation Conditioning/mortality ; Young Adult
Czasopismo naukowe
Tytuł :
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Autorzy :
Khandelwal P; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Yeh RF; Division of Pharmacology, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA.
Yu L; Division of Pharmacology, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA.
Lane A; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Dandoy CE; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
El-Bietar J; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Davies SM; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Grimley MS; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2021 Apr 01; Vol. 105 (4), pp. 891-896.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Transplantation Conditioning*/adverse effects
Abatacept/*administration & dosage
Busulfan/*administration & dosage
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*administration & dosage
Thiotepa/*administration & dosage
Vidarabine/*analogs & derivatives
beta-Thalassemia/*surgery
Abatacept/adverse effects ; Adolescent ; Busulfan/adverse effects ; Calcineurin Inhibitors/administration & dosage ; Child ; Child, Preschool ; Drug Administration Schedule ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/immunology ; Humans ; Immunosuppressive Agents/adverse effects ; Infant ; Male ; Methylprednisolone/administration & dosage ; Retrospective Studies ; Thiotepa/adverse effects ; Time Factors ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; beta-Thalassemia/diagnosis
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies